JW (Cayman) Therapeutics Co. Ltd. (HK:2126) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
JW (Cayman) Therapeutics Co. Ltd. has announced a change in its auditor, with Deloitte Touche Tohmatsu replacing PricewaterhouseCoopers due to a disagreement over audit fees. The transition to Deloitte is expected to maintain audit quality without disrupting the company’s financial reporting for the year ending December 31, 2024. This strategic move underscores the company’s commitment to aligning with industry standards and ensuring shareholder interests.
For further insights into HK:2126 stock, check out TipRanks’ Stock Analysis page.